MYELOMA MINUTE | Up To The Minute News | 12.10.2020 |
|
|
 |
Watch a Replay of the Popular Livestream: the IMWG from ASH |
The IMF’s International Myeloma Working Group, a collaborative body of some of the world’s top myeloma experts, convened at this year’s virtual 62nd American Society of Hematology (ASH) annual conference. The following doctors from the IMWG shared the latest news and trends of the treatment of myeloma from ASH: IMF Chairman of the Board Dr. Brian G.M. Durie (Cedars-Sinai Outpatient Cancer Center — Los Angeles), Dr. Thomas Martin (University of California at San Francisco — San Francisco), Dr. María V. Mateos (University of Salamanca — Salamanca, Spain), and IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope — Phoenix). Tune in now to a replay of this livestream. |
|
 |
IMF Support Group Leaders Have Their Fingers on the Pulse of ASH 2020 |
In case you missed it, the IMF’s myeloma support group leaders and patients participated in the virtual 62nd annual meeting of the American Society of Hematology (ASH), an exciting convergence of 20,000 healthcare professionals from around the world. Visit the link below to read their informative blogs from the virtual event! |
|
 |
Watch This Video of Myeloma Patient Jeff Wood Sharing His Story |
In the following video, myeloma patient Jeff Wood shares how he lives well with myeloma. Diagnosed with the disease in July 2018, Jeff soon found the IMF Support Group network within six months. He also began attending IMF's Regional Community Workshops. During a normal year, patients share their stories in-person, as part of the Brian D. Novis Grant Awards Reception at the American Society of Hematology (ASH) annual conference. Because of the pandemic, Jeff was kind enough to tell his story online. |
|
 |
Phase II HORIZON Study in Multiple Myeloma Published in the Journal of Clinical Oncology |
The peer-reviewed Journal of Clinical Oncology has published “the pivotal phase II HORIZON study evaluating intravenous melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma.” Data from this study “are the basis for the ongoing priority review of the New Drug Application to the US Food and Drug Administration (FDA), for accelerated approval of melflufen in combination with dexamethasone in triple-class refractory multiple myeloma patients, who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody.” |
|
 |
And This Too Shall Pass… |
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. The winner will be announced on April 2, 2021. Note: Bookings will be in the future based on mutual availability with you and the property owner. |
|
 |
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series |
This Week’s Question:
COVID 19 FAQ #25: How can the “Swiss cheese” model help myeloma patients stay safe? |
|
|
|
|
We Thank Our Sponsors:
|
Amgen; Bristol-Myers Squibb; Genentech; GSK; Oncopeptides, Inc.; Sanofi-Genzyme; and Takeda Oncology |
We also thank individuals like you for your continued support! |
|
Join the conversation at The International Myeloma Foundation |
Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma
www.myeloma.org |
This email was sent by: The International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607-3421 Connect with the IMF InfoLine 1-800-452-2873 |
We respect your privacy and your preferences for communications of this nature. Home • Unsubscribe • Privacy Policy |
View as web page |